Next Issue
Volume 7, 10
Previous Issue
Volume 7, 08
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
0.4
Journals
Cardiovascular Medicine
Volume 7
Issue 9
cardiovascmed-logo

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement
Cardiovascular Medicine is published by MDPI from Volume 28 Issue 1 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Editores Medicorum Helveticorum (EMH).

Cardiovasc. Med., Volume 7, Issue 9 (09 2004) – 5 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
1 pages, 116 KB  
Interesting Images
Fibrillation Auriculaire
by Jürg Schläpfer
Cardiovasc. Med. 2004, 7(9), 341; https://doi.org/10.4414/cvm.2004.01044 - 29 Sep 2004
Viewed by 53
Abstract
Données cliniques Enregistrement ECG au cours d'une cardioversion électrique (flèche, fig. 1) d'une fibrillation auriculaire chez un patient de 68 ans, hypertendu avec cardiopathie dilatée non ischémique (FE: 35%) [...] Full article
►▼ Show Figures

Figure 1

2 pages, 114 KB  
Case Report
Sténose Mitrale et Valvuloplastie Mitrale Percutanée
by Stéphane Zaza, Edoardo De Benedetti and Marco Bettoni
Cardiovasc. Med. 2004, 7(9), 337; https://doi.org/10.4414/cvm.2004.01046 - 29 Sep 2004
Viewed by 55
Abstract
Patiente russe de 44 ans sans antécédent médico-chirurgical notoire connue pour une obésité de stade I (BMI 32,4) et une notion de rhumatisme articulaire aigu dans lenfance [...] Full article
►▼ Show Figures

Figure 1

6 pages, 200 KB  
Proceeding Paper
Sind die Gen- Oder Stammzelltherapie Eine Therapeutische Option?
by Iris Baumgartner
Cardiovasc. Med. 2004, 7(9), 331; https://doi.org/10.4414/cvm.2004.01047 - 29 Sep 2004
Viewed by 53
Abstract
The aim of cardiovascular gene and stem cell therapy concepts is regeneration of vascular and myocardial cells in ischaemically damaged areas. Despite the wealth of more or less valid study results, two main directions for clinical investigation can be distinguished. Gene therapy with [...] Read more.
The aim of cardiovascular gene and stem cell therapy concepts is regeneration of vascular and myocardial cells in ischaemically damaged areas. Despite the wealth of more or less valid study results, two main directions for clinical investigation can be distinguished. Gene therapy with angiogenic growth factors in the form of repetitive intramuscular injections of naked plasmid DNA (pDNA) is simple to perform and is principally applied in clinical investigations in the field of peripheral arterial occlusive disease (“herapeutic angiogenesis”). Anumber of parallel phase II studies with nonviral pDNA for fibroblast growth factor-1 (FGF-1) are ongoing in the USA and Europe (TALISMAN studies). In ischaemic heart disease stem cell-based concepts are showing first clinical results. Adult stem cells are obtained by bone marrow puncture or ex-vivo expansion in blood of circulating stem cells also deriving from the patient’s bone marrow. After intracoronary administration what is hoped for is intensified neovascularisation of ischaemic myocardium through release of angiogenic growth factors from mononuclear bone marrow cells, and regeneration of infarcted myocardium by transdifferentiation of mesenchymal stem cells into myocardial cells. In this context the German multicentre study Transplantation Of adult Progenitor Cells in Ischaemic Heart Disease (TOPCARE-AMI study) and Bone Marrow Transfer to Enhance ST-Elevation Infarct Regeneration (BOOST study) will shortly widen our knowledge still further. Full article
►▼ Show Figures

Figure 1

6 pages, 367 KB  
Proceeding Paper
Impact of Diabetes on Acute Coronary Syndrome Management
by Marco Roffi
Cardiovasc. Med. 2004, 7(9), 325; https://doi.org/10.4414/cvm.2004.01045 - 29 Sep 2004
Viewed by 72
Abstract
Diabetic patients with non-ST-segment elevation acute coronary syndromes (ACS) are at greater risk of subsequent cardiovascular events compared with nondiabetic counterparts. However, at the same time they derive greater benefit from aggressive antithrombotic therapy, early coronary angiography, and stent-based percutaneous coronary intervention. State-of-the-art [...] Read more.
Diabetic patients with non-ST-segment elevation acute coronary syndromes (ACS) are at greater risk of subsequent cardiovascular events compared with nondiabetic counterparts. However, at the same time they derive greater benefit from aggressive antithrombotic therapy, early coronary angiography, and stent-based percutaneous coronary intervention. State-of-the-art antithrombotic therapy for diabetic patients with ACS include aspirin, clopidogrel, platelet glycoprotein IIb/IIIa receptor antagonists, and heparin or low-molecular-weight heparin. Both in the diabetic and nondiabetic population, drug-eluting stents lead to a dramatic reduction in restenosis. This exceptional therapeutic efficacy is expected to significantly improve the prognosis of diabetic patients with ACS. Full article
►▼ Show Figures

Figure 1

8 pages, 249 KB  
Proceeding Paper
Das Herz Beim Metabolischen Syndrom
by Lukas Spieker
Cardiovasc. Med. 2004, 7(9), 317; https://doi.org/10.4414/cvm.2004.01048 - 29 Sep 2004
Viewed by 59
Abstract
The definition of metabolic syndrome includes the presence of at least three of the following criteria: dyslipidaemia, hyperglycaemia, hypertension, and obesitas. The risk for cardiovascular events is strongly elevated in patients with metabolic syndrome. Also in acute myocardial infarction, hyperglycaemia worsens the outcome [...] Read more.
The definition of metabolic syndrome includes the presence of at least three of the following criteria: dyslipidaemia, hyperglycaemia, hypertension, and obesitas. The risk for cardiovascular events is strongly elevated in patients with metabolic syndrome. Also in acute myocardial infarction, hyperglycaemia worsens the outcome to a comparable degree as in patients with established diabetes. Infusion of insulin, glucose, and potassium reduces the risk for cardiac events. Glycoprotein IIb/IIIa antagonists lower the mortality in diabetic patients after percutaneous coronary intervention for acute coronary syndrome to the level of nondiabetics. In stable coronary artery disease, the mode of coronary revascularisation has been the subject of controversies. Recent clinical trials demonstrate equal mortality outcomes after percutanous and surgical revascularisation. Drug-eluting stents reduce the restenosis rate even in small vessels and long lesions as often present in diabetic patients. Drug therapy in patients with diabetes includes aspirin, statins, and inhibitors of the renin-angiotensin system––-even for primary prevention of cardiovascular disease. Full article
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Previous Issue
Next Issue
Back to TopTop